Last reviewed · How we verify
Flu Vaccine (Year 1)
The flu vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in that year's formulation.
The flu vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains included in that year's formulation. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | Flu Vaccine (Year 1) |
|---|---|
| Also known as | Fluzone® Quadrivalent High-Dose |
| Sponsor | The Jackson Laboratory |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This prepares the immune system to recognize and rapidly neutralize circulating influenza viruses, reducing infection risk and severity. The specific strains included vary annually based on epidemiological predictions.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flu Vaccine (Year 1) CI brief — competitive landscape report
- Flu Vaccine (Year 1) updates RSS · CI watch RSS
- The Jackson Laboratory portfolio CI